Development and validation of the gene expression Predictor of high-grade-serous ovarian carcinoma molecular subtype
High-grade serous ovarian cancer (HGSOC) is the commonest (about 70%), and often lethal. There had been little change in outcomes for 20 years or so but recently improved treatment is becoming available based on the genetic signature of the cancer.
Currently the evaluation of genetic status is non-standard with various centres adopting different strategies. This review evaluated an algorithm derived from the gene-expression data from 1650 tumours and applied the new analysis to 3829 cases of HGSOC.
This multi-centre study in Canada, Australia, and the USA proved the validity of the algorithm as a predictor for drug sensitivity. The authors suggest that standardised genetic testing should be used for HGSOC.
No comments:
Post a Comment